Acquisition

INDGN/SE/2026-27/62 26 October 2026 BSE Limited, National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai- 400001, India. Mumbai – 400 051, India. Scrip Code: 544172 Trading symbol: INDGN Dear Sir / Madam, Subject: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the applicable SEBI Circulars, we wish to inform you that a step-down wholly owned subsidiary of Indegene Limited (“Company”), INDEGENE PORTUGAL, UNIPESSOAL LDA, was incorporated on 23 October 2026. Indegene Ireland Limited, a wholly owned subsidiary of the Company, holds 100% of the share capital of INDEGENE PORTUGAL, UNIPESSOAL LDA. The Company received the communication confirming the incorporation of the said entity on 26 October 2026. The disclosure as required under Regulation 30 of SEBI LODR Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is mentioned in “Annexure-I”. This will also be posted on the company’s website at: https://www.indegene.com/ We request you to kindly take the same on record. Thanking You Yours Sincerely, For Indegene Limited Srishti Ramesh Kaushik Company Secretary and Compliance Officer Encl: A/a Indegene Limited Third Floor, Aspen G-4 Block, Manyata Embassy Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru- 560 045, Karnataka, India Phone: +91 80 4674 4567, +91 80 4644 7777 compliance.officer@indegene.com www.indegene.com CIN: L73100KA1998PLC102040 Annexure - I Particulars Description Indegene Portugal, Unipessoal LDA ("Subsidiary") Indegene Ireland Limited, a wholly owned Name of the target entity, details in brief such as subsidiary of the Company, holds 100% of the size, turnover etc.; share capital of INDEGENE PORTUGAL, UNIPESSOAL LDA. Turnover - Nil; the entity is yet to begin operations Whether the acquisition would fall within related party transaction(s) and whether the promoter/ The Subsidiary was incorporated in Portugal by promoter group/ group companies have any Indegene Ireland Limited. As the entity is yet to begin interest in the entity being acquired? If yes, operations, there are no related party transactions as nature of interest and details thereof and whether on date. the same is done at “arm’s length” Services for the life sciences, healthcare, and biopharmaceutical sectors; Corporate services for other affiliated entities; Content Industry to which the entity being acquired 3 development and technology support belongs services; Support services related to clinical development and medical affairs; Support services related to medical education and communications. Objects and effects of acquisition (including but not limited to, disclosure of reasons for 4 acquisition of target entity, if its business is To establish presence in Portugal. outside the main line of business of the listed entity) Brief details of any governmental or regulatory 5 Not applicable approvals required for the acquisition Indicative time period for completion of the 6 Incorporated on 23 October 2026 acquisition Consideration - whether cash consideration or 7 share swap or any other form and details of the Not applicable same Cost of acquisition or the price at which the 8 Not applicable shares are acquired Percentage of shareholding/ control acquired 100% of the shareholding is held by Indegene Ireland and/or number of shares acquired Limited, a wholly owned subsidiary of Indegene Limited Brief background about the entity acquired in terms of products/line of business acquired, date The Subsidiary was incorporated in Portugal on 23 10 of incorporation, history of last 3 years turnover, October 2026 country in which the acquired entity has presence and any other significant information (in brief)